Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

August 18, 2026

Study Completion Date

August 18, 2026

Conditions
Advanced Cancer
Interventions
DRUG

Sirolimus

"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."

DRUG

Vorinostat

"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."

DRUG

Everolimus

"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."

DRUG

Temsirolimus

"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER